Study identifier:D8310C00001
ClinicalTrials.gov identifier:NCT05850234
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects with Relapsed/Refractory Multiple Myeloma
Relapsed/ refractory Multiple Myeloma
Phase 1/2
No
-
All
80
Interventional
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Dec 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: GC012F (AZD0120) GC012F (AZD0120) will be administrated in one infusion | - |